Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oncolytics Biotech Inc

0.5610
-0.0070-1.23%
Post-market: 0.5500-0.0110-1.96%19:38 EDT
Volume:214.46K
Turnover:118.44K
Market Cap:48.58M
PE:-1.95
High:0.5680
Open:0.5588
Low:0.5466
Close:0.5680
Loading ...

Press Release: Oncolytics Biotech(R) Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Dow Jones
·
11 Apr

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

PR Newswire
·
10 Apr

Oncolytics Biotech Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Mar

Oncolytics Biotech Is Maintained at Outperform by RBC Capital

Dow Jones
·
11 Mar

Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Oncolytics Biotech (ONCY)

TIPRANKS
·
10 Mar

RBC Lowers Price Target on Oncolytics Biotech to CA$5 From CA$6, Keeps Outperform, Speculative Risk

MT Newswires Live
·
10 Mar

Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing

TIPRANKS
·
09 Mar

Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ...

GuruFocus.com
·
08 Mar

Oncolytics Q4 Net Loss Doubles, Provides Pelareorep Update

MT Newswires
·
07 Mar

Oncolytics reports Q4 EPS (10c) vs. (5c) last year

TIPRANKS
·
07 Mar

Oncolytics Biotech FY 2024 GAAP EPS C$(0.41) Beats C$(0.42) Estimate, Cash Position Of $15.9M Provides Runway Into Third Quarter 2025

Benzinga
·
07 Mar

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

PR Newswire
·
07 Mar

Press Release: Oncolytics Biotech(R) Reports Highlights and Financial Results for Q4 and Year-End 2024

Dow Jones
·
07 Mar

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks
·
05 Mar

Oncolytics Biotech Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
05 Mar

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

PR Newswire
·
25 Feb

Oncolytics provides progress update for pelareorep in pancreatic and anal cancer

TIPRANKS
·
19 Feb

Oncolytics Biotech Receives German Clearance for Pancreatic Cancer Study

MT Newswires
·
18 Feb

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

PR Newswire
·
18 Feb

Oncolytics receives noncompliance notification from Nasdaq

TIPRANKS
·
15 Feb